Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(6):411; doi:10.1093/jnci/93.6.411
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 6, 411, March 21, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Biomarkers and Bladder Cancer

Highly sensitive and specific biomarkers are attractive candidates for cancer screening programs. Hemstreet et al. (p. 427) used a panel of three predefined biomarkers (DNA ploidy, the bladder cancer antigen p300, and G-actin) to establish whether a profile based on these biomarkers could serve as a basis for risk stratification for bladder cancer in a longitudinal study of asymptomatic individuals in a Chinese cohort occupationally exposed to benzidine. The authors found that the risk of developing bladder cancer was approximately 19 times higher for workers if either DNA ploidy or p300 was positive than workers negative . . . [Full Text of this Article]

Small Molecule Inhibitor of Cdk4

Costs of Breast-Conserving Therapy and Mastectomy

15-Year Update of the Scottish Tamoxifen Trial

Antitumor Activity of an Antisense Oligonucleotide

Gene Therapy in Woodchucks for Hepatocellular Carcinoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?